Lumos has achieved enrolment of 250 patients in its BARDA-funded FebriDx® paediatric clinical study, triggering a US$670,000 milestone payment.
The study is evaluating the use of FebriDx® in children aged 2–12 years within CLIA-waived healthcare settings in the US and supports the potential expansion of FebriDx® into paediatric respiratory infection management.
Total milestone payments received under the BARDA paediatric agreement now stand at US$2.59 million, with BARDA having committed up to US$6.2 million across all study milestones.
This work builds on the recent FDA 510(k) clearance and CLIA waiver granted for FebriDx® use in patients aged 12–64 years.
Lumos CEO Doug Ward said:
“The paediatric study continues to progress, and we look forward to the day that we can support clinicians in accurately assessing acute respiratory infections in younger children.”
